UpcomingPDUFA target action date

Anktiva (nogapendekin alfa inbakicept) + BCG

ImmunityBio (IBRX)

Marketer take

A label expansion into papillary-only BCG-unresponsive NMIBC would widen the urologist audience for an existing brand and push competing bladder-sparing therapies to sharpen patient-selection messaging.

Sponsor company
ImmunityBio (IBRX)
Indication
BCG-unresponsive NMIBC with papillary disease without CIS (sBLA)
Therapeutic area
Oncology, Urology
Event
PDUFA target action date
Date
Jan 6, 2027
Status
Upcoming
Source
company press release
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move